ViiV Goes After Lupin Over HIV Drug ANDA

Law360, New York (June 30, 2011, 7:33 PM EDT) -- ViiV Healthcare Co. filed a patent infringement suit against Lupin Ltd. in Delaware on Wednesday in an effort to block the Indian drugmaker’s planned generic version of HIV drug Trizivir.

U.K.-based ViiV claims that a Lupin abbreviated new drug application infringes the patent covering Trizivir, an anti-retroviral treatment that uses three different types of drugs to better treat resistant strains of HIV.

“ViiV will be irreparably harmed by Lupin’s infringing activities unless those activities are enjoined by this court,” the complaint said. “ViiV does not have...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.